TICKERNERD
Menu
SGHTSGHTHealthcare · Medical Devices

SGHT Stock Forecast: Sight Sciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$8.26
+1.35% on the day

The 7 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $8 — -3.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 22 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$455.0M
Ticker Nerd rank
86 / 100
Median analyst target
$8.00
Analysts covering
7
Total return, dividends reinvested
1W
+1.5%
1M
+68.2%
YTD
+4.2%
1Y
+100.5%
From 52W high
−8.7%
From 52W low
+158.1%
$3.20
$9.05
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGHT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Revisions
92
Momentum
85
Accruals
68
Quality
67
Size
55
Value
51
Issuance
28
Volatility
14

Growth (93): Sales and profits are climbing, and climbing faster than before.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGHT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26SGHTHigh $12.00Median $8.00Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $8.00Median $8.00High $12.00

The green dot is the last close — the median target sits −3.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Aug 2026UBSMaintainsBuy$7.00 → $8.00
28 July 2026UBSAssumesBuy$11 → $7.00
8 July 2026CitigroupMaintainsNeutral$5.15 → $6.00
8 July 2026CitigroupMaintainsNeutral—
28 May 2026CitigroupMaintainsNeutral—
6 Mar 2026CitigroupMaintainsNeutral—
6 Mar 2026UBSMaintainsBuy—
2 Mar 2026StifelMaintainsBuy—
5 Jan 2026Piper SandlerUpgradeOverweight—
23 Dec 2025UBSMaintainsBuy—
11 Dec 2025CitigroupMaintainsNeutral—
10 Dec 2025Lake StreetMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsEqual-Weight—
10 Nov 2025Morgan StanleyMaintainsEqual-Weight—
7 Nov 2025Piper SandlerMaintainsNeutral—
21 Oct 2025Lake StreetMaintainsBuy—
7 Oct 2025CitigroupMaintainsNeutral—
28 Aug 2025NeedhamReiteratesHold—
21 Aug 2025CitigroupMaintainsNeutral—
8 Aug 2025Lake StreetUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGHT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SGHT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Sight Sciences, Inc. (SGHT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.1×

Cheaper than 93% of US stocks

Price / sales
5.5×

Cheaper than 23% of US stocks

Price / book
8.5×

Cheaper than 12% of US stocks

EV / EBITDA
−21.3×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
19.5%

Higher than 69% of US stocks

Earnings growth (YoY)
19.5%

Higher than 58% of US stocks

Gross margin
91.4%

Higher than 97% of US stocks

Operating margin
−16.6%

Higher than 22% of US stocks

Net margin
−35.7%

Higher than 12% of US stocks

Returns & dividend
Return on equity
−48.4%

Higher than 21% of US stocks

Return on assets
−10.8%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SGHT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SGHTSight Sciences, Inc.$455.0M
86
MASS908 Devices, Inc.$438.2M
84
CLPTClearpoint Neuro, Inc.$457.8M
20
SIShoulder Innovations, Inc.$459.3M
18
NPCENeuroPace, Inc.$472.3M
90
PACBPacific Biosciences of California, Inc.$407.7M
43
OFIXOrthofix Medical, Inc.$396.4M
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGHT news & analysis

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

GlobeNewsWire · 19 Aug 2026positive

Sight Sciences announced that, effective August 18, 2026, the FDA updated the Indications for Use for its TearCare System, making it the first and only meibomian gland dysfunction (MGD) treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.

Why it matters — This regulatory update gives Sight Sciences' TearCare a differentiated, first-of-its-kind labeling claim that may strengthen its market position in the MGD treatment space.

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Sight Sciences, Inc. published its Q2 2026 earnings call transcript via Seeking Alpha, covering the company's second-quarter results and management's remarks on its business performance during the call.

Why it matters — A SGHT watcher would care because the transcript offers management's own commentary on the company's Q2 2026 performance and outlook in its own words.

Sight Sciences Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Sight Sciences (SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

Why it matters — A SGHT watcher would care because the company showed revenue growth across its key business lines while cutting costs and improving its full-year financial guidance.

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

Sight Sciences, Inc. reported a second-quarter loss of $0.08 per share, narrower than the Zacks Consensus Estimate of a $0.15 loss and improved from a $0.23 per share loss in the same period a year ago. The company also topped revenue estimates.

Why it matters — The quarterly loss came in better than analysts expected and improved year over year, giving SGHT watchers a more favorable read on recent performance.

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks Investment Research · 5 Aug 2026neutral

Sight Sciences (SGHT) reported headline numbers for the quarter ended June 2026, offering insight into its performance. The report notes it may be useful to compare key metrics against Wall Street estimates and year-ago actuals.

Why it matters — SGHT watchers would care because the comparison of key metrics to analyst estimates and prior-year results helps gauge how the company's quarterly performance stacked up.

FAQ

Frequently asked questions about SGHT stock

What is the SGHT stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $8, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGHT stock a buy right now?

Of the 7 analysts covering Sight Sciences, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 86 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGHT?

As at 22 Aug 2026, Sight Sciences, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will SGHT stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -3.1% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 86 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGHT stock forecast for 2030?

No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has SGHT stock performed over the past year?

Sight Sciences, Inc. returned +100.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sight Sciences, Inc. do?

Sight Sciences Inc. is a company specializing in medical technology aimed at addressing eye diseases.

What is the latest news on SGHT?

The most recent item we track (GlobeNewsWire, 19 Aug 2026): "TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease". Sight Sciences announced that, effective August 18, 2026, the FDA updated the Indications for Use for its TearCare System, making it the first and only meibomian gland dysfunction (MGD) treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease.

Company

About Sight Sciences, Inc.

Sight Sciences Inc. is a company specializing in medical technology aimed at addressing eye diseases. The primary function of the company is to develop and commercialize innovative ophthalmic products, particularly for conditions such as glaucoma and dry eye syndrome. Their notable technologies include the OMNI Surgical System, which is designed to address the full range of outflow pathways involved in glaucoma treatment, and the TearCare System for more efficient treatment of evaporative dry eye. Sight Sciences Inc. plays a vital role in the healthcare sector, particularly in the field of ophthalmology, and is driven by a mission to transform eye care through highly effective and minimally invasive solutions. By focusing on underserved patient populations, the company not only impacts individual patient outcomes but also contributes to advancing the standards of eye disease management globally. With its headquarters in the United States, Sight Sciences is part of the broader medical technology community that continues to innovate in pursuit of better health outcomes.

CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com